. "Hrazdilov\u00E1, Krist\u00FDna" . . "6" . . . "7"^^ . . . "Hernychov\u00E1, Lenka" . "Identifikace potenci\u00E1ln\u00EDch biomarker\u016F karcinom\u016F prsu metodou SELDI-TOF MS"@cs . . "Identifikace potenci\u00E1ln\u00EDch biomarker\u016F karcinom\u016F prsu metodou SELDI-TOF MS"@cs . . . . "Identifikace potenci\u00E1ln\u00EDch biomarker\u016F karcinom\u016F prsu metodou SELDI-TOF MS" . "Backgrounds: Early diagnosis and immediate therapeutic interventions are crucial factors for successful cancer treatment. New biomarkers are needed for even earlier diagnosis, more precise histopatological classification or for prediction of treatment response. Our study was aimed at the differential analysis of protein expression profiles of cancer and non-cancer tissue from 105 patients with breast cancer. Methods and Results: Tissue lysates were analysed by SELDI-TOF MS on copper chelating chips IMAC 30. Peak intensities were statistically evaluated by Wilcoxon test with p<0,01. 28 peaks are over expressed in tumour tissue and 18 peaks are over expressed in normal tissue. Protein with molecular weight 15841 Da was identified as beta chain of haemoglobin by method peptide mass fingerprint (PMF). Conclusions: Analysis of protein expression profile by SELDI-TOF MS is able to provide a new point of view on diagnostic and tumour classification."@en . "14310" . . "\u017Daloud\u00EDk, Jan" . "RIV/00216224:14310/07:00028194!RIV10-MZ0-14310___" . . . "425364" . "Identification of potencial biomarkers of breast cancer by SELDI-TOF MS"@en . "20" . . . "Vyzula, Rostislav" . . "Hol\u010D\u00E1kov\u00E1, Jitka" . . . "SELDI-TOF MS; biological marker; breast cancer; beta-globin"@en . "0862-495X" . "11"^^ . "Identification of potencial biomarkers of breast cancer by SELDI-TOF MS"@en . . "Klinick\u00E1 onkologie" . "Nenutil, Rudolf" . "10"^^ . . . "RIV/00216224:14310/07:00028194" . "Knofl\u00ED\u010Dkov\u00E1, Dana" . "Bouchal, Pavel" . . "Vojt\u011B\u0161ek, Bo\u0159ivoj" . . . "Val\u00EDk, Dalibor" . "V\u00FDchodisko: V\u010Dasn\u00E1 diagn\u00F3za a rychl\u00E9 nasazen\u00ED c\u00EDlen\u00E9 terapie jsou kl\u00ED\u010Dov\u00FDmi faktory \u00FAsp\u011B\u0161nosti l\u00E9\u010Dby n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED. Snaha o nalezen\u00ED nov\u00FDch biomarker\u016F pro v\u010Dasn\u011Bj\u0161\u00ED diagnostiku, bli\u017E\u0161\u00ED ur\u010Den\u00ED subtypu n\u00E1doru, v\u00FDb\u011Br optim\u00E1ln\u00EDho l\u00E9\u010Debn\u00E9ho protokolu a stanoven\u00ED progn\u00F3zy odpov\u00EDdavosti na l\u00E9\u010Dbu st\u00E1le z\u016Fst\u00E1v\u00E1 jedn\u00EDm z hlavn\u00EDch c\u00EDl\u016F v\u00FDzkumu v t\u00E9to oblasti. V na\u0161\u00ED studii jsme se zam\u011B\u0159ili na diferenci\u00E1ln\u00ED anal\u00FDzu proteinov\u00FDch expresn\u00EDch profil\u016F n\u00E1dorov\u00E9 a norm\u00E1ln\u00ED tk\u00E1n\u011B 105 pacientek s diagn\u00F3zou karcinomu prsu. Metody a v\u00FDsledky: Lyz\u00E1ty tk\u00E1n\u00ED byly analyzov\u00E1ny metodou SELDI-TOF MS s vyu\u017Eit\u00EDm \u010Dip\u016F s povrchem chelatuj\u00EDc\u00EDm m\u011B\u010Fnat\u00E9 kationty (IMAC 30). Intenzity sign\u00E1l\u016F odpov\u00EDdaj\u00EDc\u00EDch jednotliv\u00FDm protein\u016Fm vzorku byly statisticky hodnoceny pomoc\u00ED Wilcoxonova testu na hladin\u011B v\u00FDznamnosti p<0,01. Bylo nalezeno 28 sign\u00E1l\u016F se signifikantn\u011B vy\u0161\u0161\u00ED hodnotou intenzity v n\u00E1dorov\u00E9 tk\u00E1ni a 18 sign\u00E1l\u016F o vy\u0161\u0161\u00ED intenzit\u011B v norm\u00E1ln\u00ED tk\u00E1ni prsu." . . "Identifikace potenci\u00E1ln\u00EDch biomarker\u016F karcinom\u016F prsu metodou SELDI-TOF MS" . "Michalov\u00E1, Eva" . . "CZ - \u010Cesk\u00E1 republika" . "P(NR8338), Z(MO0FVZ0000604), Z(MZ0MOU2005)" . "[7927215DFB20]" . . "V\u00FDchodisko: V\u010Dasn\u00E1 diagn\u00F3za a rychl\u00E9 nasazen\u00ED c\u00EDlen\u00E9 terapie jsou kl\u00ED\u010Dov\u00FDmi faktory \u00FAsp\u011B\u0161nosti l\u00E9\u010Dby n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED. Snaha o nalezen\u00ED nov\u00FDch biomarker\u016F pro v\u010Dasn\u011Bj\u0161\u00ED diagnostiku, bli\u017E\u0161\u00ED ur\u010Den\u00ED subtypu n\u00E1doru, v\u00FDb\u011Br optim\u00E1ln\u00EDho l\u00E9\u010Debn\u00E9ho protokolu a stanoven\u00ED progn\u00F3zy odpov\u00EDdavosti na l\u00E9\u010Dbu st\u00E1le z\u016Fst\u00E1v\u00E1 jedn\u00EDm z hlavn\u00EDch c\u00EDl\u016F v\u00FDzkumu v t\u00E9to oblasti. V na\u0161\u00ED studii jsme se zam\u011B\u0159ili na diferenci\u00E1ln\u00ED anal\u00FDzu proteinov\u00FDch expresn\u00EDch profil\u016F n\u00E1dorov\u00E9 a norm\u00E1ln\u00ED tk\u00E1n\u011B 105 pacientek s diagn\u00F3zou karcinomu prsu. Metody a v\u00FDsledky: Lyz\u00E1ty tk\u00E1n\u00ED byly analyzov\u00E1ny metodou SELDI-TOF MS s vyu\u017Eit\u00EDm \u010Dip\u016F s povrchem chelatuj\u00EDc\u00EDm m\u011B\u010Fnat\u00E9 kationty (IMAC 30). Intenzity sign\u00E1l\u016F odpov\u00EDdaj\u00EDc\u00EDch jednotliv\u00FDm protein\u016Fm vzorku byly statisticky hodnoceny pomoc\u00ED Wilcoxonova testu na hladin\u011B v\u00FDznamnosti p<0,01. Bylo nalezeno 28 sign\u00E1l\u016F se signifikantn\u011B vy\u0161\u0161\u00ED hodnotou intenzity v n\u00E1dorov\u00E9 tk\u00E1ni a 18 sign\u00E1l\u016F o vy\u0161\u0161\u00ED intenzit\u011B v norm\u00E1ln\u00ED tk\u00E1ni prsu."@cs . .